Keyword: Securities and Exchange Commission
The co-founders of Outcome Health and several former executives have been charged by the Department of Justice in a $1 billion fraud scheme.
On the verge of a merger with Pfizer's Upjohn, Mylan is closing an SEC investigation into EpiPen for a cool $30 million.
Companies routinely update analysts, but a new SEC order for tiny TherapeuticsMD offers a lesson—or reminder—about when to keep quiet.
Teva’s $519 million settlement with the U.S. government in 2016 was meant to clear its name. Now, former leaders will foot their end of the bargain.
J&J has been defending itself against thousands of lawsuits claiming harm from talc, but it also as a criminal probe to contend with, Bloomberg reports.
Sanofi's Bioverativ buy buoyed its rare disease lineup. But for a Swiss man, the deal allegedly brought some illegal gains—and a U.S. criminal case.
The Justice Department and SEC subpoenaed J&J for asbestos-testing documents at the center of lawsuits linking its iconic baby powder to cancer.
FDA slaps Akorn with warning letter following an inspection of its sterile injectables plant in Illinois.
The former Teva chairman was accused of working in sync with others to control "penny stocks," and sold them after questionable promotions.
A federal jury ruled Aveo's ex-CFO David Johnston made untrue statements about tivozanib and that he made money as a result.